1111 Stewart Avenue, Bethpage, NY 11714 P 516-803

Transcription

1111 Stewart Avenue, Bethpage, NY 11714
P 516-803-2304
F 516-803-2303
www.lustgartenfoundation.org
research
diagnosis
prevention
cure
‘05 ANNUAL REPORT
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
our mission
To advance the
scientific and medical
research related to
the diagnosis,
treatment, cure and
prevention of
pancreatic cancer by:
> Increasing funding and support of research into
the biological mechanisms and clinical strategies
related to the diagnosis, treatment, cure and
prevention of cancer of the gastrointestinal tract
with primary emphasis on adenocarcinoma of
the pancreas;
> Facilitating and enhancing the dialogue among
members of the medical and scientific
communities about basic and clinical research
efforts that relate to pancreatic cancer;
> Advocating an increase in the annual budget of
the National Cancer Institute with emphasis on
research related to pancreatic cancer; and
> Heightening the public’s awareness of pancreatic
cancer diagnosis, treatment, and prevention, and
providing informational support for pancreatic
cancer patients, their families and friends.
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
Charles F. Dolan
Chairman
Linda Gosden Robinson
Marcia Lustgarten
Charles R. Schueler
William Bell
Sheila Mahony
Alan D. Schwartz
James L. Dolan
Matthew Modine
Andrew Lustgarten
Robert F. Vizza, Ph.D.
President
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
direction
Note the theme of this year’s annual report, as depicted on the cover, HOPE. For years, a diagnosis of
pancreatic cancer brought with it a sense of despair and devastation. Now, thanks to increased research,
there are more reasons for hope and optimism than at any time in the past. There are over 100
compounds presently in clinical trials, each offering hope for a breakthrough in treatment therapies. The
development of a mouse model, partially funded by a Lustgarten Foundation grant, is a vital
breakthrough in our understanding of the disease and in the development of more effective therapies.
The National Cancer Institute’s dramatic increase in funding for pancreatic cancer research has
established "Pancreatic Cancer Programs of Research Excellence" at three leading comprehensive cancer
centers: University of Alabama at Birmingham, M.D. Anderson Cancer Center in Houston, Texas, and the
Mayo Clinic in Rochester, Minnesota.
Alongside these NCI multi-year support grants, the Lustgarten Foundation in 2005 initiated its own
"Focused Research Program". In addition to the $100,000 in annual grants into broad areas of pancreatic
cancer research, the Foundation introduced multi-year grants of $250,000 per year for up to three years
in specific areas of research: Early Detection and Novel Therapies. It is envisioned that this focused
research, driven and supported by the Foundation, will lead to significant progress in dealing with the
fourth-leading cause of cancer deaths – pancreatic cancer.
We want to acknowledge the work of the Scientific Advisory Board and its outgoing Chairman,
Dr. Joseph Simone. We thank Dr. Simone for his many years of leadership, and welcome Dr. Robert Mayer,
Director, Center for Gastrointestinal Oncology, Dana Farber Cancer Institute, as the new Chairman of the
S.A.B. Similarly, our thanks go to our Corporate Advisory Board for their continuing support, especially
the Chairman, President Jimmy Carter.
message from the board of directors
Charles F. Dolan
Chairman
Marcia Lustgarten
Linda Gosden Robinson
Andrew Lustgarten
James L. Dolan
William Bell
Sheila Mahony
Charles R. Schueler
Matthew Modine
Alan D. Schwartz
President
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
dear friends:
Continuing this year’s theme of "HOPE", the following
pages of this Annual Report detail the highlights of the
Foundation’s activities and the progress achieved in
2005. This year we introduced our Focused Research
Projects (FRP) featuring a dramatic increase in the
amount of dollars per grant, along with a multi-year
commitment to promising research proposals. While we
will continue our annual grants of $100,000, the intent
of the FRP is to attract and encourage world-class
researchers to develop more comprehensive, and thus more promising, research projects. Two of these
FRP grants were awarded in 2005, and, in 2006, our Board has authorized two rounds of competitive
FRP grants along with our continuing annual grants. To date, The Lustgarten Foundation for Pancreatic
Cancer Research has awarded over $14 million in research grants.
In order to support these grants, you have generously supported our many fundraising activities:
■ The inaugural Beating The Odds Poker & Casino Night at Oheka Castle was an outstanding
success that attracted more than 330 guests and raised $239,000.
■ The 2nd Annual Marc Lustgarten Memorial Golf Outing at the exclusive Golf Club of Purchase
welcomed 68 Golfers & raised over $144,000.
message from the president & ceo
■ The annual Holiday Rock & Roll Bash, featuring Cablevision Chief Executive Officer and
Lustgarten Foundation Board member James Dolan, and his Band JD & the Straight Shot, was
another huge success and raised over $1 million for research.
■ The 5th annual New York Pancreatic Cancer Research Walk attracted over 3,000 participants
and raised over $750,000.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
message
■ The inaugural Chicago Pancreatic Cancer Research Walk helped to raise over $150,000 with
more than 650 walkers coming out to support our research. In 2006, we will add another
Walk for our supporters in the Boston area.
In addition, 2005 activities included our 7th International Pancreatic Cancer Scientific Conference,
hosted by Memorial Sloan-Kettering Cancer Center. The theme of this year’s conference was "Pancreas
Cancer 2005: State-Of-The-Art", and was co-chaired by Dr. David Kelsen, Chief, Gastrointestinal
Oncology Service at Memorial Sloan-Kettering Cancer Center and Dr. Joan Massague, Chairman, Cell
Biology Program at Memorial Sloan-Kettering Cancer Center. Over 250 of the worlds leading scientists
dealing with pancreatic cancer were in attendance.
As a result of our increased focus on research, the need for a Director of Science became apparent.
We are grateful to Dr. Ralph Hruban, Director of the Division of Gastrointestinal/Liver Pathology at
Johns Hopkins Hospital, for agreeing to serve in that capacity. In 2005, Dr. Joseph Simone, our 1st
Chairman of the Scientific Advisory Board ended his term in that role. We wish to publicly acknowledge
and thank him for his leadership. Dr. Robert Mayer, Director, Center for Gastrointestinal Oncology, Dana
Farber Cancer Institute, has been appointed as the new Chair of the Scientific Advisory Board. He brings
great experience and wisdom, and we look forward to his leadership.
We would like to offer our sincere gratitude to our Board of Trustees and Corporate and Scientific
Advisory Boards for their guidance and support. We would also like to offer our heartfelt thanks to you
for your critically important support of The Lustgarten Foundation for Pancreatic Cancer Research.
Without each of you, we would be unable to offer pancreatic cancer patients and their families a most
important element: HOPE.
Sincerely,
President
Enes J. Carnesecca
Executive Director & Chief Executive Officer
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
scientific advisory board
Chairman
Joseph V. Simone,
M.D.
Chairman Elect
Robert J. Mayer,
M.D.
Clinical Director
Emeritus, Huntsman
Cancer Institute;
Professor Emeritus,
Pediatrics & Medicine
University of
Utah; President,
Simone Consulting
Director, Center for
Gastrointestinal
Oncology, DanaFarber Cancer
Institute; Professor
of Medicine,
Harvard Medical
School
James
Abbruzzese, M.D.
Tyler Jacks, Ph.D.
Chairman & Professor
of Medicine,
Gastrointestinal
Medical Oncology
University of Texas
M.D. Anderson Cancer
Center
Investigator, Howard
Hughes Medical
Institute;
David H. Koch
Professor of Biology,
Massachusetts
Institute of
Technology
Center for Cancer
Research
Director of Science
Ralph Hruban, M.D.
Director of Science,
Professor of
Pathology &
Oncology,
Director, National
Familial Pancreas
Tumor Registry
Johns Hopkins
Hospital
Joel E. Tepper,
M.D.
Professor & Chair,
Department of
Radiation Oncology
UNC School of
Medicine
Ronald DePinho,
M.D.
David P. Kelsen,
M.D.
Robert F. Vizza,
Ph.D.
Professor of Medicine
and Genetics,
Harvard Medical
School
Chief, Gastrointestinal
Oncology Service
Edward S. Gordon
Chair in Medical
Oncology, Memorial
Sloan-Kettering
Cancer Center
President,
The Lustgarten
Foundation
Douglas B.
Evans, M.D.
Joan Massagué,
Ph.D.
Daniel D. Von
Hoff, M.D.
Professor of Surgery,
University of Texas
M.D. Anderson
Cancer Center
Chairman, Cell
Biology Program,
Memorial
Sloan-Kettering
Cancer Center;
Investigator, Howard
Hughes Medical
Institute
Professor of
Medicine, Professor
of Pathology,
Molecular & Cellular
Biology, Director, Cell
Therapeutics
Programs, Arizona
Health Sciences
Center
Judah Folkman,
M.D.
Margaret Tempero,
M.D.
Andrew L.
Warshaw, M.D.
Surgeon-in-Chief
Emeritus; Director,
Surgical Research Lab,
Children’s Hospital;
Julia Dykman Andrus
Professor of Medicine;
Professor of Pediatric
Surgery, Harvard
Medical School
Deputy Director,
UCSF Comprehensive
Cancer Center;
Chief, Division of
Medical Oncology,
University of
California, San
Francisco
Surgeon-in-Chief,
Chairman, Depart.
of Surgery,
Massachusetts
General Hospital;
W. Gerald Austen
Professor of Surgery,
Harvard Medical
School
Our world renowned Scientific Advisory Board is comprised of researchers and clinicians from leading
cancer institutions in the United States. This Board helps to guide our research funding activities by reviewing
grant applications and making recommendations to our Board of Directors. The Scientific Advisory Board
helps provide the leadership necessary to forge real progress in the fight against pancreatic cancer.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
The Lustgarten Foundation &
Memorial Sloan Kettering
work together to advance
Pancreatic Cancer Research
ON JUNE 23RD and 24th, 2005, the
Lustgarten Foundation for Pancreatic
Cancer Research and Memorial Sloan
Kettering Cancer Center joined together
to create a comprehensive medical
conference devoted to pancreatic cancer.
They brought together molecular
biologists, clinical researchers,
oncologists, surgeons, pathologists,
radiologists, dieticians, epidemiologists,
psychologists and others to discuss their
impact on pancreatic cancer.
Co-chaired by David Kelsen, M.D. and
Joan Massague, Ph.D. of
Memorial Sloan Kettering, they were
clearly excited about the progress in
pancreatic cancer research and
treatment, but they tempered their
enthusiasm by pointing out how much
further the science needs to travel to
successfully impact a patient’s care and
treatment. They both discussed how
much more there is to be learned. For
example, molecular events are starting to
be dissected, but more potential drug
targets are needed. There is a need for
more effective screening programs.
Adjuvant therapies are not yet available
and metastatic disease is still not curable.
featured talks:
Epidemiology of Pancreatic Cancer
Alfred I. Neugut, M.D., Ph.D.
Professor of Medicine and Public Health
Columbia University
Why does someone get pancreatic cancer?
Dr. Neugut, M.D., Ph.D., spoke about risk factors
for pancreatic cancer. Currently, smoking is the
only environmental factor strongly associated
with pancreatic cancer. Tobacco is responsible
for 35% of pancreatic cancer cases in the U.S.
For the remaining 65% of pancreatic cancer
patients, 5-10% of the cases can be attributed
to having inherited faulty genes. For the others,
the cause is not known. There may be many
different combinations of environmental factors
that can lead to pancreatic cancer. More
research is needed to determine what these
environmental and endogenous factors may be.
Pancreatic Cancer:
More familial than you thought
Anirban Maitra, MBBS
Departments of Pathology and Oncology
Johns Hopkins University School of Medicine
Dr. Anirban Maitra, MBBS, discussed the genetic
causes of pancreatic cancer. Dr. Maitra explained
studies done of families and specific high-risk
populations, which established that pancreatic
cancer is inherited in about 10% of the
pancreatic cancer population. The underlying
genetic defect that results in familial
predisposition to pancreatic cancer is known in
only a minority of kindred, and the search
continues to identify the gene or genes
responsible for the vast majority of familial
pancreatic cancers. Of the several gene
mutations already known to be associated with
a higher risk of developing pancreatic cancer,
mutations in the breast cancer gene, BRCA2,
are currently the most common cause.
Outcome with Standard Surgery/
Controversies in Surgery-Cystic
Tumors, PanIN
Keith Lillemoe, M.D.
One of the holy grails in pancreatic cancer
research is to learn more about the early stages
of the pancreatic cancer so it can be treated at
a pre-invasive stage, thereby prolonging patient
survival. Keith Lillemoe, M.D., spoke about
lesions in the ducts of the pancreas that may be
precursors of invasive pancreatic cancer.
They’re called Intraductal Papillary Mucinous
Neoplasms (IPMNs) and Pancreatic
Intraepithelial Neoplasia (PanIN). Are IPMNs and
PanINs clues for invasive pancreatic cancer?
Lillemoe and colleagues are studying these
lesions to gauge their importance and find ways
to detect them earlier.
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
conference
Rare Pathologic Subtypes
David Klimstra, M.D.
Department of Pathology
Memorial Sloan Kettering Cancer Center
Most pancreatic tumors originate in the ductal
cells of the pancreas. However, sometimes
tumors originate in the acinar or islet cells.
Much less is known about the biology and
clinical behavior of tumors of acinar and islet
(endocrine) cell origin. David Klimstra, M.D.,
presented findings from his group’s hunt for the
molecular fingerprints that distinguish the rarer
tumors from the more common ductal
adenocarcinomas.
Signaling Pathways in Pancreas Cancer
Richard Kolesnick, M.D.
Molecular Pharmacology & Chemistry
Richard Kolesnick, M.D., spoke about a potential
new treatment for pancreatic cancer. The
therapy is an antisense oligonucleotide inhibitor
of a gene called KSR-1, a ‘henchman’ of the
mutant form of the gene k-Ras. Over 90% of
human pancreatic cancers are caused or
sustained by mutations in k-Ras which make the
gene overactive. Blocking mutant Ras, or a
protein it interacts with, such as KSR-1, could
inhibit the growth of cancer cells in which Ras is
inappropriately active. Dr. Kolesnick is planning
to conduct phase I clinical trials in conjunction
with the NCI on this treatment.
Hedgehog Pathway in Pancreatic Cancer:
Pancreas Cancer
Matthew Hebrok, Ph.D.
Assistant Professor in Residence
University of California, San Francisco
Matthew Hebrok, Ph.D., has identified a gene
called ‘hedgehog’ that could be a drug target. In
mice with pancreatic cancer, using a compound
known to block hedgehog signaling reduces the
size of their tumors. An even more promising
find by Dr. Hebrok and colleagues is that by
simultaneously inhibiting hedgehog and wnt,
another protein involved in pancreatic
development, even greater tumor size reduction
occurs in tumor cell lines.
results from the study ESPAC-1 (European Study
Group for Pancreatic Cancer), published in
2004, that showed no benefit of adjuvant (post
surgery) chemoradiation over surgery alone.
Dr. Berlin also believes that while ESPAC-1
demonstrated a benefit to chemotherapy, it
neither proved nor disproved the utility of all
Is pancreatic cancer in mice similar to
chemoradiation. This is due to several issues,
pancreatic cancer in humans? Eric Sandgren,
including the way in which chemoradiation was
V.M.D., Ph.D., thought so, at least on some
administered in the trial. However, while others
levels. Dr. Sandgren created mice that develop
have said that because ESPAC-1 does not
pancreatic cancer to determine if the mice
disprove other forms of chemoradiation and we
tumors look and behave like human tumors.
should therefore continue using it, Dr. Berlin
For example, in mice pancreatic acinar cells,
believes that other methods of administering
Sandgren and colleagues overexpressed the
chemoradiation are reasonable to study on
genes c-myc, TGFalpha, and mutant k-Ras, which
clinical trial. In the adjuvant setting, however,
are known to cause pancreatic cancer in
radiation should still be considered
humans. The mice developed tumors similar to
investigational only. The benefit of using
human tumors. However, there were slight
radiation has not been demonstrated. Dr.
differences, reinforcing the need for testing
Neoptolenos emphasized that the study
potential therapies in humans even when the
demonstrated there still is a benefit to using
therapies prove successful in mice.
adjuvant chemotherapy, without the radiation,
over surgery alone. He felt that despite the
State-of-the-Art Current Staging:
ESPAC-1 trial demonstrating no benefit of
PET, MRI, CT
chemoradiation following surgery, radiation has
Peter Pisters, M.D.
increased the effectiveness of chemotherapy in
M.D. Anderson Cancer Center
treating other cancers. Dr. Neoptolenos
How do you know when a patient’s pancreatic
explained that we need more treatment options
tumor is localized (not metastatic) and clear of for pancreatic cancer because the ESPAC-1 trial
major arteries and veins so that it can be safely demonstrated that chemotherapy is beneficial
removed by surgery or that surgery can be
as an adjuvant therapy, but not "as much as we
avoided? To be able to answer that question
would like it to be". One of the major challenges
effectively, Dr. Peter Pisters recommended:
in using radiation therapy for pancreatic cancer
■ More detailed CT scan-reporting by
patients is where to aim the radiation beam.
radiologists regarding clearance of the
Neoptolenos is hopeful that as technology
tumor from the major veins and arteries
improves, this problem may lessen. Successful
■ Coupling CT scans with a diagnostic test that radiation therapy may also be achieved by
measures a patient’s CA 19-9 levels, a
altering the treatment schedules.
marker of pancreatic cancer and its stage
Neoadjuvant Chemotherapy
■ Using staging laparoscopy to identify
John Hoffman, M.D.
patients who should not undergo further
Attending Surgeon
surgery because of metastasis when CT
Surgical Oncology Fox Chase Cancer Center
scans are hard to interpret
John Hoffman, M.D., spoke about using
■ Recommending patients to regional centers
neoadjuvant therapy, which is therapy given
of care because high volume of pancreatic
before surgery, usually when a tumor is hard to
surgeries is associated with longer patient
remove. Dr. Hoffman cited many small scale
survival.
studies that demonstrated neoadjuvant therapy
is either helpful or prolongs patient survival. He
gave the following reasons: 1) it assures that a
Post-Op Adjuvant Therapy is Indicated
patient will get chemo- and radio-therapy,
Point/CounterPoint Discussion
which often doesn’t happen after surgery,
Jordan Berlin, M.D.
because of insurance reasons; 2) it mitigates
Co-Director Vanderbilt University-Irgram
the rush for surgery, thereby allowing more
Cancer Center
time to find metastatic spread of the cancer; 3)
John Neoptolenos, M.D., Ph.D.
it can reduce the size of locally advanced
Department of Surgery
tumors which would otherwise have no chance
for a margin-free resection. However, a phase III
University of Liverpool
trial to support or deny the application of
Frequently, after patients have been operated
neoadjuvant therapy is needed once the best
on to remove a pancreatic tumor, they would
systemic chemotherapy and the role and
receive a combination of chemo- and
dosage of radiotherapy have been established.
radiotherapy. However, in point/counterpoint
discussions between John Neoptolenos, M.D.
and Jordan Berlin, M.D., Dr. Berlin cited the
Mouse Models of Pancreatitis,
Pancreatic Cancer
Eric Sandgren, V.M.D., Ph.D.
Department of Pathobiological Sciences
School of Veterinary Medicine/
University of Wisconsin
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
FDA Review of Criteria for Approvability
of New Agents in Pancreatic Cancer
Vicky Goodman, M.D.
Division of Oncology Drug Products
Food & Drug Administration
At the time of the conference, 1996 was the last
time a drug was approved for pancreatic cancer.
Vicki Goodman, M.D., an official at the FDA, spoke
about the challenges for cancer drug approvals.
For a cancer drug to be deemed successful and
thus ready for marketing, it must meet phase III
endpoints. These are based on clinical benefit, not
biological benefit such as tumor size reduction,
which is accepted only as an endpoint for phase II
trials. The requirement for phase III trials with
endpoints of established clinical benefit such as
survival, applies to approval of drugs through the
standard or "regular" approval process. Under
accelerated approval, drugs intended to treat
serious or life-threatening diseases (including
pancreatic cancer) may be approved on the basis
of an improvement in an endpoint considered
"reasonably likely to predict clinical benefit." The
requirements are that they are an improvement
over available therapy and that the sponsor
performs additional studies to confirm that the
drug has a beneficial effect on an established
"clinical benefit" endpoint. Clinical benefit means
improvement in patient reported symptoms and
survival. However, trials with such endpoints need
a large number of patients and long patient
follow-up times, making the trials harder to
conduct. Other surrogate endpoints are being
sought. The FDA is now considering “time to
progression” of disease and “progression-free
survival” as alternatives to a “survival” endpoint
in some disease settings.
detailed detection of pancreatic lesions. The
goal is to learn how the different lesions
correlate with biological activity so they can
eventually be used as surrogates for survival in
assessment of therapy responses. If they
correlate with time of progression to disease,
this would be a relatively measurable endpoint
and make clinical trials easier to conduct.
However, if one is just looking at tumors in
order to measure response to therapy, there
remains the challenge of how to capture nontarget responses. Thus, Dr. Schwartz cautioned
that in addition to imaging of pancreatic lesions,
one would still need to use other biologically
relevant criteria to assess treatment response.
Novel Therapeutics
Hedy Kindler, M.D.
University of Chicago Cancer Research Center
Robert Wolff, M.D.
GI Medical Oncology
M.D. Anderson Cancer Center
Recent advances in cancer therapy involve
“targeted” therapies, which means the treatment
is directed against the action of a specific
pathway believed to play a role in the growth or
spread of cancer. Robert Wolff, M.D., and Hedy
Kindler, M.D., updated the audience on targeted
pancreatic cancer therapies that are being tested
in clinical trials. The most widely investigated
targets for pancreatic cancer therapies are Ras,
EGFR, and VEGF, explained Dr. Wolff. Ras and
EGFR are involved in cell growth pathways. VEGF
promotes angiogenesis, or new blood vessel
Systemic Therapy:
growth, which enables tumors to survive.
Review or Recently Completed Clinical
Trials and Current Standard of Care
However, Dr. Wolff pointed out that inhibiting just
Eileen O’Reilly, M.D.
one of these targets is not good enough — the
cancer then just overuses another pathway. Thus,
Most pancreatic cancer patients unfortunately the latest efforts focus on combination therapies
(40-50%) have metastatic, stage IV, inoperable
that inhibit targets in different pathways.
cancer where only chemotherapy and
supportive care are possible. Eileen O’Reilly,
Immunotherapy
M.D., spoke about therapies for treating such
Dan Laheru, M.D.
patients. The standard single agent
chemotherapy is now gemcitabine.
Johns Hopkins University School of Medicine
However, trials are ongoing to determine the
best way to administer gemcitabine. Combining Curing cancer with a "shot" (vaccine) is an active
gemcitabine with other cytotoxic agents, such area of investigation. Daniel Laheru, M.D., spoke
about three clinical trials Johns Hopkins is
as 5-FU, cisplatin, irinotecan, and oxaliplatin,
are also under investigation. So far no
involved with among the numerous ongoing trials
significant improvement has been documented, in immunotherapy for pancreatic cancer. Like
but the gemcitabine/oxaliplatin combination
most cancers, pancreatic cancer has a way of
may be of benefit for vigorous individuals with
hiding from the immune system, thereby
bulky disease. There are also signs of a
escaping its wrath. The goal of immunotherapy is
promising combination of gemcitabine with
to give the immune system a boost in finding and
erlotinib. Novel therapies being investigated
fighting the unwanted cancer cells.
include EGFR antibodies, anti-angiogenic
agents, cox-2 inhbitors and cell-cycle inhibitors. Dr. Laheru's approach involves obtaining a
patient's own tumor cells, genetically modifying
Imaging & Response Assessment
them to 'unmask' them and reintroducing the
Larry Schwartz, M.D.
tumor cells to the patient in the form of a
Director, Magnetic Resonance Imaging
vaccine, in order to spur his/her immune system
into action.
Larry Schwartz, M.D., spoke about advances in
CT, PET and MRI imaging that are enabling more
Nutritional Support
Moshe Shike, M.D.
Cancer Prevention & Wellness Program
Nutrition management of pancreatic cancer
patients is very important. Almost 80% of
patients have lost weight by the time of their
cancer diagnosis. Furthermore, by the time of
death, most patients have lost 25% or more of
their pre-illness body weight. This begs the
question of whether improving a patient’s
nutrition can improve their quality of life and
chances of survival. Moshe Shike, M.D., discussed
situations where nutritional support makes a
difference and instances where it doesn’t, based
on evidence from published studies.
Pain Management in Pancreas Cancer
Kathleen Foley, M.D.
Pain & Palliative Care Service
Pain is one of the biggest fears of pancreatic
cancer patients. At diagnosis, 63% of patients
report some kind of pain, and 21% report
moderate pain. Why so much pain? Are cytokines
responsible? Is it because the tumors are close to
nerve endings? When is the appropriate time to
intervene, for whom, and how? These are the
types of questions addressed by the research
group of Kathleen Foley, M.D.
Depression in Pancreas Cancer Patients
Steven Passik, M.D.
One would think it is only natural for a person
diagnosed with pancreatic cancer to be
depressed because of the disease’s poor
prognosis. However, there is evidence that many
pancreatic cancer patients are depressed even
before they know they have the disease. Thus,
there is reason to believe medical/biological
reasons, not just existential ones, are the cause
of patients’ depression. Steven Passik, M.D.,
discussed the many pieces of data
demonstrating that pancreatic cancer patients
have elevated cytokine levels which may be
associated with their depression. Thus, lowering
cytokine levels may be a way to manage and
may diagnose the disease. Treatments currently
under investigation for treating depression in
pancreatic cancer patients include cytokine
antagonists and/or anti-inflammatory agents.
In the meantime, Dr. Passik suggests that the
correct use of antidepressants can also relieve
depression symptoms. He recommends that
oncologists learn to use 3 antidepressants
either alone or in combination, taking into
account the drugs’ side effects and the patient’s
particular characteristics (such as whether or
not he/she is experiencing nausea, needs to
gain weight, etc.).
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
2005 grants
Paul Fisher, MPH, Ph.D.
Professor, Clinical Pathology
Columbia University College of
Physicians & Surgeons
Exploiting Defects in Molecular
Circuitry to Selectively Kill
Pancreatic Cancer Cells
Recent studies have allowed this
team to develop a proof-of-concept
for the hypothesis that defects in
molecular circuitry in pancreatic
cancer cells can be exploited to
develop a potential viral-based
therapy for treating pancreatic
cancer. In this study, Dr. Fisher
intends to increase the stringency of
evaluation of this viral-based therapy
(Terminator Virus) by defining
whether it has anti-tumor activity in
a pancreatic cancer mouse model.
Should this prove successful, the
next step would be to begin to
develop a Phase 1 Clinical Trial.
Kimberly Kelly, Ph.D.
Instructor, Radiology
Massachusetts General Hospital
Development of Molecular Imaging
Agents for Early Detection of
Pancreatic Cancer
Dr. Kelly’s goal is to develop new
imaging approaches for the early
detection of pancreatic cancer.
This will be accomplished by utilizing
recently developed mouse models
that recapitulate the genetics of
human disease. Sophisticated
chemical and biological approaches
will be used to find novel tags that will
allow the earliest forms of pancreatic
cancer to be pinpointed, which will
ultimately enhance the detection of
pancreatic cancer by MR imaging or
endoscopic optical imaging.
The Lustgarten Foundation is excited to announce our
2005 and 2006 RFA/RFP grant recipients.
The Foundation’s ability to fund the work of these
great researchers is directly attributable to the
generosity of our donors. Thank you for your support.
Richard Kolesnick, M.D.
Member, Molecular Pharmacology &
Therapeutics
Memorial Sloan Kettering
Cancer Center
Development of KSR
Phosphorothioate Antisense
Oligonuucleotides in the Treatment
of Pancreatic Cancer
More than 90% of human pancreatic
cancer manifests a 12 KRAS mutation
that can be identified early in the
disease and may be considered
causative in its pathogenesis.
The long term goal of this study is to
optimize the therapeutic potential of
KSR1, a kinase suppressor of RAS1, in
the treatment of RAS dependent
human malignancies, and thereby
identify a new therapeutic target.
Steven Leach, M.D.
Chief, Division Surgical Oncology
Johns Hopkins Medical Institutions
Zebrafish Model of Early
Pancreatic Cancer
Dr. Leach is developing a transgenic
zebrafish model of pancreatic cancer.
Zebrafish are susceptible to a
spectrum of tumor types very similar
to those observed in cancer patients.
Thousands of transgenic zebrafish
can be studied per week, providing
an opportunity to study pancreatic
cancer genetics and treatment, and
thereby providing a powerful new
system for novel pancreatic cancer
drug discovery.
Roland Schmid, M.D.
Technical University of Munich
The Role of Notch Signaling
in the KRAS Mouse Model
Pancreatic Cancer
Pancreatic cancer is almost always
characterized by a mutation in the
KRAS gene, which leads to
constitutive activation of the RAS
signaling pathway. Dr. Schmid and his
team will combine the model of the
KRAS G12D mouse model with
conditional Notch 1&2 ablation to
understand the role of Notch
signaling in early, as well as late,
stage carcinogenesis. This could lead
to the initiation of therapeutic
studies.
Amy Tang, Ph.D.
Assistant Professor of Surgery
Mayo Clinic
SIAH: A Novel Biomarker of
Pancreatic Cancer Progression and
Therapeutic Implications
Dr. Tang’s study will identify novel
RAS targets for protein turnoverbased anticancer therapies and
contribute to the understanding of
the role that KRAS plays in
promoting pancreatic cancer
development. Knowledge gained
from this work has promising
translational value and should
provide new insights and avenues for
diagnosis, therapeutic intervention,
and treatment of pancreas cancer.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Sarah Thayer, M.D., Ph.D.
Assistant in Surgery
Massachusetts General Hospital
Shh Links Chronic Inflammatory
Injury to Pancreatic Carcinogenesis
Chronic inflammation has been tied
to the formation of cancer in several
organs, one of which is the pancreas.
Sonic Hedgehog (Shh), is an
important developmental factor and
is believed to be an early activator of
pancreatic cancer. Dr. Thayer’s aims
for this project are to characterize
expression of Shh in the pancreas in
response to inflammation and to
investigate the character of the
epithelium that expresses Shh, a
potential site of cancer formation.
Understanding these early events in
the formation of pancreatic cancer
may identify risk factors that may
aid in cancer prevention or early
diagnoses.
2006 grants
Steven D. Leach, M.D.
Professor of Surgery and Oncology
Johns Hopkins University
High-Throughput, In-Vivo Screening
for Novel Pancreatic Cancer Drugs
Using the Zebrafish
This project seeks to apply the
tremendous power of the zebrafish to
the identification of new pancreatic
cancer drugs. The group has
successfully generated the first
genetically engineered zebrafish in
which KRAS, a pancreatic cancer
gene, is specifically activated in
pancreatic tissue. These transgenic
zebrafish now provide us the unique
opportunity to pursue highthroughput screening for new
pancreatic cancer drugs. Because of
the small size requirements and low
cost associated with raising zebrafish
embryos, this system will allow us to
rapidly screen tens of thousands of
novel chemicals for anti-pancreatic
cancer efficacy in a way that is simply
not feasible in studies involving mice
or human patients.
David Tuveson, M.D., Ph.D.
Assistant Professor
Hematology and Oncology
Trustees of the University of
Pennsylvania
Novel Anti-KRAS Strategies in
Ductal Pancreatic Cancer
The recent development and
successful clinical application of
drugs which, in several cancers,
inhibit the protein product of
essential mutant genes known as
“oncogenes”, indicate the
importance of identifying such
essential oncogenes in all tumor
types and developing drugs that can
counteract the function of that
oncogene. Oncogenic mutations in
the KRAS protein likely represent
such an essential protein in
pancreatic cancer. However, no
therapies are available today for
patients with pancreatic cancer that
attempt to inhibit the mutant KRAS
protein. We propose to use a KRASdependent mouse model of
pancreatic cancer, which our
laboratory has developed, to develop
newer models in order to determine
the important features of an
effective anti-KRAS therapeutic
agent in pancreatic cancer. Armed
with this information, we will assess
several promising anti-KRAS
preclinical compounds in these
model systems in an effort to select
relevant agents for clinical
development in pancreatic cancer.
Joshua Mendell, M.D., Ph.D
Assistant Professor
Johns Hopkins University School
of Medicine
The Role of MicroRNA’s in the
Pathogenesis of Pancreatic Cancer
Mechanisms that control when genes
are turned on and turned off are
critical for maintaining normal
cellular behavior. For example,
inappropriate activation of a gene
that promotes the growth of cells
can lead to the development of a
tumor, which is essentially a mass of
abnormally proliferating cells. Less
than five years ago, an entirely new
mechanism of regulating the level of
activity of a gene was discovered.
This new regulatory pathway relies
on tiny molecules called microRNAs
which, when produced by a cell, are
able to turn off specific sets of
genes. Since their discovery,
microRNAs have attracted a great
deal of attention in the scientific
community because of their potential
to influence cellular behavior and,
therefore, human disease. It is now
appreciated that many different
types of cancer cells produce
abnormal amounts of microRNAs,
and this subsequently can influence
malignant cellular behavior.
Nevertheless, the role of microRNAs
in the development of pancreatic
cancer has not yet been studied.
This project proposes to initiate
these efforts by classifying abnormal
microRNA function in pancreatic
cancer cells. To accomplish this, we
will utilize an experimental tool
developed in our laboratory which is
capable of measuring the abundance
of hundreds of microRNAs
simultaneously. After identifying
microRNAs that are abnormal in this
type of cancer, we will use
experimental tumor models to
directly study their ability to
influence pancreatic cancer
development. This project has the
potential to reveal entirely new
cellular mechanisms that are
abnormal in pancreatic cancer and
thus may ultimately allow the
development of new therapies for
this disorder.
Lewis Charles Murtauh, Ph.D.
Assistant Professor
University of Utah
Interdependence of Notch and
KRAS Signaling in Pancreatic
Tumorigenesis
We hypothesize that differentiation,
the process by which growing,
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
immature stem and progenitor cells
are converted to quiescent, mature
cells, serves to prevent pancreatic
tumor formation and progression.
In other types of cancer, continued
malignancy appears to require
that differentiation be blocked,
and we focus here on a cellular
signal that we have shown to be
a major inhibitor of pancreatic
differentiation. This signal, known
as the Notch pathway, is active in
human pancreatic tumors as well
as in a mouse model of the disease.
We propose to use these mice, in
conjunction with another line that
our team has generated, to test
whether Notch signaling promotes,
and is required for, pancreatic
tumorigenesis. The Notch pathway
can be targeted for pharmacological
inhabitation, and we will perform a
“clinical trial” of a highly bioactive
drug to determine its effect on
mouse pancreatic cancer. We
anticipate that positive results from
this work will result in further study
of this pathway and its
pharmacological antagonists in
human patients.
Recent evidence has suggested that
AIB1 is directly oncogenic, and in this
study we will determine the role of
AIB1 in PanCa development using a
directly relevant mouse model.
These studies will contribute to
understanding of human PanCa
development. Ultimately we envision
AIB1 as a potential target for
therapeutic inhibition which could
prevent a broad spectrum of growth
factor and nuclear receptor effects in
PanIN and PanCa development. The
pharmaceutical industry has ongoing
projects to develop small molecule
inhibitors of AIB1 as a transcriptional
coactivator. The current project
would validate AIB1 as such a target
in PanCa.
Roland M. Schmid, MD
Jens T. Siveke, MD
Technical University Munich
The Role of Notch Signaling in
Pancreatic Cancer Development
Anna T. Riegel, Ph.D.
Professor of Oncology
Georgetown University
The Role of the Nuclear Receptor
Coactivator AIB1 in the Early
Preneoplastic Stages of Pancreatic
Cancer
AIB1 is a protein which activates the
expression of cellular genes. When
overexpressed, AIB1 can make cells
become proliferative and invasive,
and they will grow anchorage
independently. In other words, AIB1 is
oncogenic and drives tumor
formation. AIB1 probably does this by
activating a panel of growth factor
signaling pathways which are known
to drive preneoplastic changes in the
human pancreas. We have published
that AIB1 is not expressed in the
normal pancreas but has increased
expression correlating with
advancing stage of PanIN and PanCa.
The transformation of normalfunctioning pancreatic cells into
preneoplastic precursor cells is the
initial event culminating eventually in
the development of divesting
pancreatic cancer. Understanding
which cells are susceptible to
oncogenic stress and why should
increase our knowledge of the
molecular factors involved. This may
identify genetic or environmental
regulators of the initial events
leading to this practically treatmentresistant disease. In previous and
ongoing studies, we identified Notch
signaling as an early key regulator
switch of preneoplastic conversion.
Gene expression profiles, as
well as analyses regarding the
differentiation status of KRASG12D
mutated pancreatic cells with or
without Notch signaling ablation, will
be performed. Incidence and
phenotype of invasive pancreatic
cancers in KRASG12D mutated cells
vs. Notch ablated mice will be
studied, and this will help define the
role of Notch signaling for early
transformation and progression of
grants
cells in pancreatic carcinogenesis.
Experiments using inhibitors of
Notch signaling should help define
their effect on pancreatic
carcinogenesis.
Diane M. Simeone, M.D.
Associate Professor
University of Michigan
Medical Center
Pancreatic Cancer Stem Cells
Over the last several years, it has
been increasingly realized that
cancers may arise from small
populations (less than 5%) of
“cancer stem cells” which are
responsible for the propagation
and metastasis of tumors. These
stem cells are of clinical interest as
they typically have a different gene
expression profile than the much
larger bulk of differentiated cancer
cells within a tumor. These “cancer
stem cells” are much more resistant
to standard therapies used currently
to treat cancer. This is relevant for
pancreatic cancer in that it is very
likely that currently used therapies
targeting bulk cancer cells have little
effect on the stem cell population
within the tumor. In this grant, we
propose to do further work to
identify a pancreatic cancer stem cell
population and to perform molecular
studies to better understand the cell
population, thereby leading to more
effective treatment approaches for
pancreatic cancer.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
In 2005, The Lustgarten Foundation continued to grow its library of
important educational materials, adding to our “Ask An Expert” series three
new important topics: Pain, Depression, and Treatment Review.
In each issue of these educational materials, Reina Marino, M.D., Lustgarten
Foundation friend and supporter, and Virginia Cravotta, News12 Long Island
Senior Correspondent, interview an expert in the field of pancreatic cancer.
In this year’s interviews, Kathleen M. Foley, M.D. focused on pain, Steven D.
Passik, Ph.D. focused on depression, and James L. Abbruzzese, M.D. focused
on treatment review.
We would like to thank all of these experts for taking the time to help us
produce these important patient materials.
Ask an Expert:
Educational
information for
Pancreatic
Cancer Patients
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
The inaugural “Beating The Odds: Poker & Casino Night” was held at Oheka
Castle on April 14th. Co-Chaired by Matthew Modine, Veteran Actor and
Lustgarten Foundation Board member, and Len Novick, Senior Managing
Director of Estreich & Company, the event was an outstanding success,
attracting more than 330 guests and raising $239,000.
Calling upon special friends of The Lustgarten Foundation, this event was
created to help increase awareness and resources for The Foundation’s
research efforts.
beating
the
odds
In addition to an evening of dining and gambling inside this enchanted
castle built in 1918 by Otto Kahn as a private residence, there was a special
auction that raised more than $21,000. Auction items included a dinner
for 4 at Rao’s Restaurant in New York City, a dinner for 10 aboard a private
yacht, a walk on role with the Rockettes at Radio City Music Hall’s
Christmas Spectacular, and the opportunity to be a NY Knicks ball kid at a
Knicks home game.
Co-Chairs Matthew Modine and Len Novick and their outstanding Executive
Committee Members are joining together again on May 11th to host the
second annual “Beating The Odds: Poker & Casino Night.” This year’s event
will recognize Kalmon and Neil Dolgin of Kalmon Dolgin Affiliates, Inc. for
their dedication to The Lustgarten Foundation and pancreatic cancer
research. For more information, please contact Ann Walsh at:
516-803-2304
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
2nd Annual
Marc Lustgarten
Memorial Golf
Outing Raises
$144,000 for
Research
September 19, 2005
marked a special day as
participants arrived at
the exclusive Golf Club of
Purchase for the 2nd
Annual Marc Lustgarten Memorial Golf
Outing. The beauty of the event was only
to be matched by the weather. After a
wonderful brunch, the golfers hit the
course for the shotgun start. Golfers of
all levels took their swings at the
challenging Golf Club of Purchase and, in
the end, no matter their level of play,
everyone was ecstatic about the
enjoyable round they had.
Burton Wallack, outing co-chair,
addressed the golfers at the
dinner following the outing.
Burton spoke of his memories
golfing with Marc, who was a less
traditional golfer, and the fun times they
had on the golf course together. "My
family and I are so pleased we can help
continue this special event in memory of
Marc," said Burton. Marcia Lustgarten,
outing co-chair, offered her thanks and
appreciation to all of the golfers,
sponsors, family members and friends
who were able to attend and
make the event so special. She
also spoke of the great
importance of continuing this
fight against pancreatic cancer so that
we can help put an end to this terrible
disease. The Lustgarten Foundation
offers our special thanks to The Wallack
Family, Marcia Lustgarten, Jennifer and
Robert Schenk, and the entire golf
committee for all their hard work and
effort that made this day so perfect. We
would also like to once again thank all of
the golfers and the sponsors for their
participation and for their help in funding
this important pancreatic cancer
research event. We give special thanks to
the New York Knicks for donating the
"Ball Kid" experience auction item,
providing a special opportunity for a
youngster to serve as ‘Ball Kid’ during a
New York Knicks game.
We would also like to acknowledge
the generous sponsors that
made this year’s event so wonderful:
Accolade Building Maintenance Corporation
Belkin
Burden, Wenig & Goldman
Brend Renovation Corporation
The Byrd Family
Danielle Uniform Cleaners
The Feinstein Family
H & D Maintenance Company Inc.
Mr. & Mrs. Richard Hochman
Ideal Roofing
Isseks Brothers, Inc.
Mr. & Mrs. Neil Koenig
Mr. & Mrs. Henry Miller
Maria & Guy Muzio
Permasign Corporation
Tuchman, Katz, Schwartz, Gelles, Korngold & Weiss
Winston American Transportation Inc.
Mr. & Mrs. Morton Rothberg
Mr. & Mrs. Richard Schenk
Mr. & Mrs. Jack Wurgaft
Mr. Fred Udell
Mr. Tom Hoch
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
corporate advisory board
The Honorable
Mel Karmazin
Sumner M. Redstone
President & CEO
Sirius Satellite Radio
Chairman & CEO
Viacom, Inc.
Gerald M. Levin
Tom Rogers
Retired Chief
Executive Officer
AOL/Time Warner, Inc.
Chairman
TRget Media, LLC
John C. Malone
Sir Howard Stringer
Chairman
Liberty Media
Corporation
Chairman & CEO
Sony Corporation
of America
Vice Chairman,
Sony Corporation
John Hendricks
Rupert Murdoch
Robert C. Wright
Chairman & CEO
Discovery
Communications,
Inc.
Chairman & Chief
Executive Officer
News America, Inc.
Vice Chairman &
Executive Officer
General Electric
Company
Chairman & CEO
NBC Universal
Jimmy Carter
Honorary Chairman
Frank A.
Bennack, Jr.
Vice Chairman of the
Board and Chair of
the Executive
Committee
The Hearst
Corporation
Barry Diller
Chairman & CEO
InterActive Corp.
Our prestigious Corporate Advisory Board is led by Honorary Chairman President Jimmy Carter and
joined by leading cable and media executives. This Board helps to share our message with millions of
Americans by supporting a national media campaign that includes on-air public service announcements
and print ads.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
We would like to acknowledge the
generosity of all our sponsors:
2005
rock & roll bash
On December 8th, over 1,000 friends
and supporters filled B.B. King’s Blues
Club & Grill in New York City’s Times
Square to help support the Lustgarten
Foundation’s 5th annual Holiday Rock &
Roll Bash.
The evening was headlined by JD & The
Straight Shot, who were “created in the
spirit of Creedence Clearwater Revival
and Dr. John. They have a bluesy, bar
band feel, and Dolan's swaggering
vocals are, at turns, slightly reminiscent
of Tom Waits and Randy Newman.” (NY
Post – 10/9/05). The “standing room
only” crowd was rocking the house all
night long. While stars and celebrities
arrived throughout the night, the
excitement reached its peak when
Santa Claus made his way in with the
world-famous Radio City Rockettes.
We would like to thank JD & The
Straight Shot’s lead singer, Cablevision
Systems Corporation’s President &
Chief Executive Officer and Lustgarten
Foundation Board Member James
Dolan, for all of his hard work in helping
to create the Holiday Rock & Roll Bash.
This annual event not only offers the
Lustgarten Foundation the national
recognition needed to garner
supporters to work to combat this
disease, but also, since its inception
in 2001, has helped to raise over
$4 million in support of critical
pancreatic cancer research.
Cablevision Systems Corp.
Scientific-Atlanta, Inc.
Siemens Communications Inc.
Willkie Farr & Gallagher LLP
Bank of America
Cisco Systems
Debevoise & Plimpton
JPMorgan
Madison Square Garden
NBC Universal Cable
News Corporation
Rainbow Media Holdings
Sullivan & Cromwell LLP
Sun Microsystems
The Bear Stearns Companies Inc.
Verizon Communications
Warner Music Group
WLNY TV55
Amdocs Broadband Cable & Satellite
Division
BBB Architects, JLL, Severud & M-E
Engineers
Disney and ESPN Media Networks
Merrill Lynch
Robert & Veronique Pittman
Sidley Austin Brown & Wood LLP
Sloane & Company
Accessory Network
Citigroup, Inc.
Cushman & Wakefield
Discovery Networks
Farrell Fritz, P.C.
Gardner Nelson & Partners, Inc.
HBO
KPMG LLP
Levon Graphics Corp.
MTV Networks
NBA-WNBA
New Jersey Devils
Skadden, Arps, Slate, Meagher & Flom LLP
Sundance Channel
Synchronoss Technologies Inc.
The Jones Day Foundation
Time Warner Inc.
Vornado Realty Trust
Wachovia Securities
Arnold & Porter LLP
Calyon Corporate and Investment Bank
E! Networks
Gemstar TV Guide, International
Kronish Lieb Weiner & Hellman LLP
Oxygen Media
Showtime Networks Inc.
Tribune Media Services
MEDIA PARTNERS
Multichannel News
Broadcasting & Cable
Variety
TelevisionWeek
CableWorld
CableFAX
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
2005 New York
Pancreatic Cancer
Research Walk
Old Westbury Gardens once again
hosted the Annual Lustgarten
Foundation Pancreatic Cancer
Research Walk. In an amazing turnout
and show of support, the Lustgarten
Foundation raised over $750,000 from
the over 3,000 walkers in attendance,
more than 1,000 of which were new
friends joining us for the first time.
Mr. Charles Dolan, Chairman of the
Lustgarten Foundation’s Board of
Directors, shared his excitement about
the great strides we are making in the
field of pancreatic cancer research. He
offered his heartfelt thanks to all of
those on hand to celebrate the special
day, giving special thanks to Colleen
McVey, News 12 Anchor, who joined us
as the Master of Ceremonies for the
event and to the 100 incredible
volunteers who helped make the event
run so smoothly.
the advancements that have been
made, as well as those that are on the
horizon, in the scientific field in the
fight against pancreatic cancer.
On behalf of our Board Members and
everyone associated with The
Lustgarten Foundation, deepest thanks,
and we hope to see you on July 30th
for our 2006 New York Pancreatic
Cancer Research Walk.
“The tide is turning, and with
continued research we will find a cure,”
noted Lustgarten Foundation President
Dr. Robert Vizza, as he shared some of
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Inaugural Chicago
Pancreatic Cancer
Research Walk
On September 25th, 650 dedicated
friends joined together to help create the
first annual Chicago Pancreatic Cancer
Research Walk!!! Held at the beautiful
Chicago Botanic Garden in Glencoe, IL,
and raising more than $170,000, it
insured that one additional research
project could receive critical funding!
In addition, this walk helped pave the
way for The Lustgarten Foundation to
begin to conduct Pancreatic Cancer
Research Walks all over the country.
As an example, on October 15, 2006,
The Lustgarten Foundation will also be
conducting the Inaugural Boston
Pancreatic Cancer Research Walk.
The Chicago Walk would not have been
possible without the commitment and
efforts put forth by our Chicago Walk CoChairs. Robert Forrer and his daughter,
Rebecca Forrer, Philip Arnold and his
daughter, Alyson Arnold, and Gail
Zugerman and her husband, Dr. Charles
Zugerman, all of whom lost loved ones to
this disease, joined forces and worked
relentlessly to solicit sponsors, cultivate
volunteers, promote the walk and
organize logistics for the day.
Together with many new friends, they are
joining us again to insure that the
September 10, 2006 Chicago Pancreatic
Cancer Research Walk is also a great
success. If you live in the heartland of
this wonderful country, please mark your
calendar and join us. It’s a great day
dedicated to a great cause!
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
community connections
Maryland Student Pitches in…
The Lustgarten Foundation would like to
acknowledge Leora Horowitz, age 16, for
her hard work in support of, and her
dedication to, the Chicago Walk. Although
she lives in Maryland, Leora raised over
$3,000 for Pancreatic Cancer Research in
memory of her father, Arthur Horowitz,
who passed away on September 2, 2005.
Leora is an inspiration to all of us at The
Lustgarten Foundation.
I Want to be a Lifesaver
One of our top fundraisers for the
inaugural Chicago Pancreatic Cancer
Research Walk has proven to be a topnotch entrepreneur who has raised more
than $10,000. Earlier this year, 13-year-old
Danielle Tasiopoulos lost her godfather,
Bill Tasiopoulos, to pancreatic cancer.
Since that time, she has been trying to
figure out ways to become a “lifesaver”
and help others with this disease. She
came up with a wonderful idea. She, along
with her sister, cousins and friends,
started making their own jewelry, called
"Life Savers". Her creations are some of
the best sellers in the Illinois area, selling
over 400 necklaces so far. As Danielle
says, "These necklaces give everyone a
chance to be a Lifesaver." Danielle’s Walk
team, "I Want to be a Lifesaver", quickly
surpassed their fundraising goal, and
Danielle plans to keep raising money
throughout the school year. Danielle’s
fundraising efforts were also featured in
the September 15th issue of the Pioneer
Press in Illinois and can be seen on our
website at www.lustgarten.org. The
Lustgarten Foundation is proud to have
friends like Danielle, and we know that
with her help, we will find a cure.
Capital District In My
Community Walk
Barbara Mantoni Santaniello
Research Fund
PIPER’S WALKERS & JOAN
OF THE HEART
Donations Pass
$140,000 Mark
On June 26th, Piper’s Walkers and Joan of
The Santaniello Fund’s Fifth Annual
Memorial Golf Tournament was held on
July 22, 2005 at the Franconia Golf
Course in Springfield, Massachusetts. This
outing raised $25,000 in support of the
Barbara Mantoni Santaniello Research
Fund, which brings the fund’s support of
the Lustgarten Foundation to a total of
more than $140,000. The Santaniello
Research Fund, organized in memory of
Barbara Mantoni Santaniello who lost her
battle with pancreatic cancer, has held
golf tournaments yearly since 2001. The
fund raises money for the Lustgarten
Foundation in support of its research in
the field of pancreatic cancer.
the Heart held their “In My Community
Walk” in Delmar, NY, a suburb of Albany.
Almost 40 walkers joined together for the
second year to raise over $4,000 to help
fight pancreatic cancer. Walkers came from
as far away as Vancouver, BC, New York
City, Massachusetts and Florida. We would
like to congratulate both Piper’s Walkers
and Joan of the Heart for their amazing job
and for all of their hard work. Additionally,
we would like to acknowledge two corporate
sponsors for this year’s walk: The Golub
Foundation of Price Chopper Supermarkets
and Dunkin’ Donuts in Delmar, NY.
Dedicated To The One
We Loved
“On July 27, 2004, Pat Ericson died of
pancreatic cancer. That fall, her children
and I decided we wanted to do more to
support pancreatic cancer research, and
we decided on a walk in her memory.
Family and friends, of which she had
many, joined in the walk and in the fight
against pancreatic cancer. We received
donations from as far west as New Mexico,
as far north as Ontario and Minnesota, as
far east as Long Island, and as far south
as Florida. The Walk was very successful
for a first time event, as we raised
$2,960. With this success, another
fundraising event is planned for next
year.”
-Contributed by her husband Ron Ericson
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
High School Students
Bike Ride
On June 2, 2005, Lauren Koppel and six
friends, all high school seniors, left
Rockville Centre on bicycles and headed
to Montauk as part of a fundraiser for The
Lustgarten Foundation. From Rockville
Centre they made an overnight stop in East
Islip. From East Islip they made their way to
Westhampton Beach and then to Montauk.
We would like to thank Lauren for leading
this event, and we applaud her and her
friends for all of their hard work and
dedication to finding a cure for pancreatic
cancer.
Wonders", tore the house down. Belvis
wowed the packed crowd as she sang all
of the King’s classic hits. It was a night to
remember when Belvis entered the
building. We congratulate Barbara (Belvis)
and all those who participated in the show
for a rousing success, and we thank them
all for their hard work that raised
$4,173 in the fight against
pancreatic cancer.
Amy Kistler
Half Ironman Triathlon
Office Fundraising
The 2005 holiday season parties were
plentiful, and, while enjoying the
merriment of the season, Optimum
Lightpath gathered their promotional
products and sold them at the employee
party. Who couldn’t pass up $1.00
t-shirts, or 2 for $1.00 coffee mugs! There
were books and pens, scarves and ties. It
was a fun-filled evening where many
partygoers were even able to fill some
stockings! November is Pancreatic Cancer
Awareness month. To raise awareness,
Angelo Salustri suggested to his Human
Resources Department at Darwin
Partners, Inc. that the company enjoy
casual Fridays in November to benefit The
Lustgarten Foundation for Pancreatic
Cancer Research. On Casual Fridays,
employees wore jeans and donated $5.00.
At the end of the month, a donation was
made to The Lustgarten Foundation.
Curl–o–Rama
BBeellvviiss Haass
EEnntteerreedd tthhee
BBuuiillddiinngg
Belvis Live From Bohemia
On June 23rd, 2005, the Airport
Playhouse Theatre in Bohemia, NY offered
a special show, but this was unlike any
show before, as it featured the legendary
Belvis. Comedian Dr. Harry Friedman
opened the night. Dr. Friedman, who has
performed nationally and has written for
The Carolines Comedy Hour and
Showtime Specials, got the crowd warmed
up for the main attraction. Barbara
"Belvis" Del Piano of Manorville, the only
female Elvis Presley tribute artist in New
York, starred in the fundraiser in memory
of Ralph N. Del Piano (Barbara's uncle).
Belvis and her back-up vocalists, "The
Amy Kistler, who lost her father, Dale
Kistler, to pancreatic cancer a mere five
weeks from the time of diagnosis, took the
initiative to honor her father’s memory
and, at the same time, benefit the
Lustgarten Foundation by garnering
supporters of her participation in a half
ironman triathlon. Amy was looking for a
way to raise awareness of this terrible
disease and to help support an
organization that funds research for early
detection and treatment. The triathlon,
held on September 11th, at Duke
University, consisted of a 1.2-mile swim, a
56-mile bike ride and a 13.1-mile run. While
this event posed a significant challenge, it
is nothing compared to the pain and
suffering of so many from this devastating
disease. The donations of the sponsors
supporting Amy’s triathlon resulted in her
successfully raising over $5,000 to help
support pancreatic cancer research. The
Lustgarten Foundation is proud to have
friends like Amy and we thank her for all
of her hard work.
In the first quarter of 2005, Stephanie
Coleman organized the second annual
“Curl-o-Rama” charity curling tournament,
which took place in Maryland. Stephanie,
her friends and family continue this
annual event in memory of her father,
Daniel Coleman. Each year the curling
tournament and a silent auction help raise
money and awareness for pancreatic
cancer research.
Festival of Hope
Agatha Rice organized the first Festival of
Hope to benefit The Lustgarten
Foundation. The event took place on
August 14th at Beenzy’s Bar & Grill in
Bellmore, NY. Fun, food, music and drinks
provided the backdrop for a wonderful day
honoring the memory Agatha’s mother,
who died of pancreatic cancer. Donated
raffle prizes and door prizes ensured that
most everyone went home with a
treasure.
In Memory of Ginny
The annual fall street fair in Stewart
Manor, NY is a fun-filled day for the
residents of this lovely hamlet. Salone Di
Capelli, a high-fashion hair salon, takes
advantage of the day to honor the
memory of their former owner, Ginny
Tetro. The proceeds of a raffle and the
sale of salon products at the fair provided
The Lustgarten Foundation with important
dollars in the fight to find a cure for
pancreatic cancer.
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
Give, So Cancer Can’t Take
When my mother passed away on
August 11, 2002, pancreatic cancer had
violated our family, and I knew there had
to be something we could do to save
another family from having to experience
a loss like ours. My mom said that after
she was gone we would have to find a way
to move forward and to not let the pain
derail our lives. She knew that would be
difficult, but she said to find, or create,
beautiful doors to open after one would
close… This fundraiser is one of those
beautiful doors we opened, and she
guided us to it! I started “Give, So Cancer
Can’t Take” in 2002. The first event took
place on November 16 at CH Robinson as
a casual day and Happy Hour. All
donations went to the Lustgarten
Foundation, and we raised $1,800. In
2003, the event expanded, and we began
having it at Tiffany’s Sports Bar and Grill
in St. Paul, MN. Supporters enjoyed food
and spirits for a few hours while they
listened to the Minneapolis/St. Paul local
talents! We are excited to announce that
the 4th Annual “Give, So Cancer Can’t
Take” was held December 3, 2005 and
raised over $8,500 from over 400 people
in attendance! This year the 5th Annual
“Give, So Cancer Can’t Take” benefit will
take place on Saturday, December 2, 2006
at Tiffany’s Sports Bar and Grill.
- Contributed by Rebecca Forrer
Circle of Hope
On October 1st, Frank Hague completed the
fifth annual Circle of Hope to benefit the
Lustgarten Foundation. Before sunrise, in
the company of some great people from
the Mount Desert Island based Eden
Athletics Club, a 12 mile run from Northeast
Harbor to Bar Harbor began. From Bar
Harbor, with a great send off from his
running crew, Frank began the 38 mile sea
kayak segment of the journey. The paddle
leg went well, and by the end of the day he
Five years ago, after losing his father,
Howard Shapiro, to Pancreatic Cancer,
Kenneth Shapiro, along with his wife,
Farah, and his sister, Deborah, decided to
create the Howard Shapiro Memorial Fund.
This fund directly benefits The Lustgarten
Foundation in its efforts to raise money
for Pancreatic Cancer Research. On
August 1, 2005, the Shapiros held the 5th
Annual Howard Shapiro Memorial Fund
Golf Tournament at Shackamaxon Golf
and Country Club in Scotch Plains, NJ.
The event had more than 80 golfers in
attendance and raised over $10,000 for
promising pancreatic cancer research.
Eddie Ivanoski Memorial Golf
Tournament
GOLF OUTINGS
Paul Bearducci Memorial Golf
Outing
The sixth annual Paul Bearducci Golf
Outing took place on September 10th at
the Green Valley Golf Course in
Tuscarawas County. The weather was
perfect, and all of the participants had a
wonderful time. We extend special thanks
to Erica McMillen-Miller who organizes this
annual event.
5th Annual
Howard Shapiro Memorial
Fund Golf Tournament
Nearly 200 individuals and businesses
participated in The Eddie Ivanoski Memorial
Golf Tournament which took place on
October 7 at The George Wright Golf Course
in Boston, MA. Whether by sponsoring a
hole, donating raffle prizes or signing up to
play, each participant was making a special
tribute to Eddie Ivanoski and helping in the
fight against pancreatic cancer.
Zoine Golf Outing
On August 17, 2005, the Zoine Family held
the 1st Annual Anthony R. Zoine Golf
Outing at Calverton Links in Calverton, NY.
The beautiful weather helped make the
day even more perfect as over $4,400
was raised for Pancreatic Cancer
Research.
community
had experienced an interesting mix of sea
conditions. Frank would like to thank
everyone involved for all they did to make
the Circle of Hope 2005 a successful event.
The Lustgarten Foundation would like to
acknowledge Frank for his continued effort
to support pancreatic cancer research.
connections
get your company involved!
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
online giving shows amazing
2005 marked an amazing year for
the Lustgarten Foundation’s online
fundraising efforts. The number of
gifts received through our website
increased from 2,307 to 6,228 - an
increase of almost 170%!
The large number of gifts also led us
to the overall increase in online
fundraising dollars. 2005 showed an
increase to over $400,000 raised
online, an increase from $174,000 in
2004. Our Walk fundraising website
has seen the largest increase - a
growth from $116,000 in 2004 to
almost $300,000 in 2005. The
Lustgarten Foundation is excited by
growth
these increases and our donors’
willingness to give via our secure
Internet connection. Since our
addition of online fundraising in
2003, donations to the Lustgarten
foundation have risen over 1,000%.
Thank you for you generosity.
FUNDS RAISED FOR RESEARCH
$500,000
$403,198
$400,000
$300,000
$174,130
$200,000
$100,000
$39,276
$0
2003
2004
2005
NUMBER OF ONLINE DONATIONS
7500
6228
5000
2307
2500
499
0
2003
2004
2005
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
how you can help
The Lustgarten Foundation for
Pancreatic Cancer Research is:
■ Dedicated to finding better
treatments and a cure for
pancreatic cancer;
■ Funding innovative research
studies designed to advance
pancreatic cancer discovery;
■ Creating opportunities to help
stimulate scientific dialogue within
the medical and research
communities about pancreatic
cancer;
■ Leading a national public
awareness campaign on the need to
increase resources for pancreatic
cancer research;
■ Providing the most up-to-date
information to patients, their
families and the medical
professionals that serve them.
We invite your participation to help
increase and expand upon these vital
activities.
By joining with The Lustgarten
Foundation, you are helping to
guarantee that we can continue
supporting high quality, leading-edge
pancreatic cancer research.
You are joining a team that is
dedicated to finding better treatments,
improving patient information and
care, and greatly increasing the
scientific dialogue about the
disease in the scientific and
medical communities.
ways you can help
■ Cash Donations
■ Memorial or Tribute Gifts
Mail checks to:
The Lustgarten Foundation for
Pancreatic Cancer Research
1111 Stewart Avenue, Bethpage, NY 11714
Remember a loved one or celebrate a
special occasion by making a donation
to The Lustgarten Foundation. The
Foundation will send a thank you card
to you and an acknowledgment card to
the honoree, or, in the case of a
memorial donation, to the
family member.
Credit card donations:
Call 1-866-789-1000 or visit
www.lustgarten.org.
Recurring Donations:
Select a donation amount that fits
your budget and choose to have an
automatic charge placed on your
credit card each month.
■ Additional Giving
Opportunities
* Gifts of appreciated securities
* Establishment of a charitable
remainder trust, or a charitable
lead trust
* Real estate
* Life insurance
* Wills and Bequests
■ Workplace Programs
Ask your human resources personnel if
there is a company-sponsored payroll
deduction program and/or matching
gifts program for charitable donations
in which you can participate.
For more information regarding special giving opportunities in support of The Lustgarten Foundation,
please contact the Office of Development at 1-866-789-1000.
Donations to The Lustgarten Foundation are tax-deductible to the fullest extent of the law.
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
donors & founders
The Lustgarten Foundation for Pancreatic Cancer Research would
like to pay tribute to the many individuals, corporations and
foundations whose generous donations and gifts-in-kind help to
make our work possible. The following listing reflects contributions
to the Foundation from January 1 through December 2005.
Founders
Anonymous
Bill and Ellen Bell
Cablevision Systems Corporation
Mr. & Mrs. Frederick DeMatteis
Mr. & Mrs. James L. Dolan
Mr. & Mrs. Amos Hostetter
Mr. & Mrs. John T. Lockton III
The Lustgarten Family
McMullen Family Foundation
Mr. & Mrs. F. F. Randolph, Jr.
Mr. & Mrs. Leonard Tow
Charles B. Wang Foundation
President’s Circle
$100,000 + cumulative
Anonymous
Bank of America
Barbara Montani Santaniello Research
Fund, Inc.
Bear, Stearns & Company
Bill and Ellen Bell
Mrs. Dorothy Daly
Eli Lilly and Company
H. J. Kalikow & Co., LLC
Mr. and Mrs. Amos Hostetter
ImClone Systems, Incorporated
KPMG LLP
Levon Graphics Corporation
Mr. and Mrs. John T. Lockton III
The Lustgarten Family
Miramax Films
Morgan Stanley
News Corporation
Pharmacia & Upjohn, Inc.
Rainbow Media Holdings
Mr. and Mrs. F. F. Randolph, Jr.
Scientific Atlanta, Inc.
Siemens Communications
James S. Swinehart Memorial Fund
The Bernice and Milton Stern Foundation
Time Warner
Mr. Leonard Tow
Charles B. Wang Foundation
Karen Zissu-Magidson Memorial Fund
2005 Donors
$100,000 +
Mrs. Dorothy Daly
$50,000 - $99,999
Anonymous
Bank of America
Eli Lilly and Company
James S. Swinehart Memorial Fund
Levon Graphics Corporation
Morgan Stanley
Robert and Joan Penardi Foundation, Inc.
Scientific Atlanta, Inc.
Siemens Communications
Sun Microsystems, Inc.
The Bernard Lee Schwartz Foundation, Inc.
The John Hartford Foundation, Inc.
Willkie Farr & Gallagher LLP
$25,000 - $49,999
Barbara Montani Santaniello Research
Fund, Inc.
Bear, Stearns & Company
Bristol-Myers Squibb
Debevoise & Plimpton LLP
Frank J. Antun Foundation
Genentech, Inc.
General Electric Foundation
KPMG LLP
Lightpath
Mrs. Marcia Lustgarten
Karen Zissu-Magidson Memorial Fund
Sullivan & Cromwell
The Starr Foundation
Thomasville Home Furnishings, Inc.
Verizon Communications
Warner Music Group
WLNY TV 55
Mrs. Kathryn Wriston
$10,000 - $24,999
Accessory Network Group
Amdocs Broadband, Cable Satellite, Inc.
Bill and Ellen Bell
Bethpage Federal Credit Union
Mr. Aaron Braun and Ms. Joan
Pauline DeHovitz
Mr. John M. Cilo
Citigroup Inc.
Cushman & Wakefield, Inc.
Discovery Networks
Disney and ESPN Media Networks
Employees of Cygnus, Inc.
Estreich & Company, Inc.
Farrell Fritz, P.C.
Gardner Nelson & Partners, Inc.
Gemstar TV Guide
Gibson, Dunn & Crutcher LLP
Mr. and Mrs. Arthur Goldberg
HBO
Howard Shapiro Memorial Fund
ICOS Corporation
ImClone Systems, Incorporated
ION Computer Systems
KEYSPAN
Lockheed Martin Commercial Space
Systems
Sheila Mahony and Charles Riggs
Mr. Fraydun Manocherian
Merrill Lynch
Milken Family Foundation
MTV Networks, Inc.
National Basketball Association
New Jersey Devils
Old Oaks Foundation
OSI Pharmaceuticals
Pittman Family Foundation
Quadrangle Group, LLC
Sanofi Aventis
Ms. Kathryn Schulberg
Sidley Austin Brown & Wood
Silva Salustri Benefit Fund
Sloane & Company
Sundance Channel
Synchronoss Technologies Inc.
The Jones Day Foundation
The Mailman Foundation, Inc.
The Richardson Pratt, Jr. Family
Time Warner
Vornado Realty Trust
Wachovia Securities
West New York Restoration of CT, Inc.
$5,000 - $9,999
Mr. Charles Alter
Amerada Hess Companies
Amy Kistler & Friends
Anonymous
Arnold & Porter LLP
Ms. Atkinson
AXA Foundation
Mr. Ira Balsam
Bernice and David Gotlieb
Philanthropic Fund
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
Mr. Richard D. Bogner
Calyon Corporate and Investment Bank
Mr. John Campbell
Mr. and Mrs. Louis Carnesecca
Century Elevator
Coleman Family Curling Event
Convergys
Credit Suisse First Boston
Mr. Robert Dineen, Jr.
Mr. and Mrs. Kalmon Dolgin
Mr. Johnathan Durst
E! Television Networks
Ms. Karen Fahy
Ms. Anita Fleishman
Fred Smith Plumbing & Heating Co., Inc
Hercules Corp
Ms. Inda Hightower-McDonald
Mr. Randall Hube
JC Penney Company, Inc.
JP Morgan Chase
Mr. and Mrs. Armenag Kalaydjian
Kauff, McClain & McGuire, LLP
Kronish Lieb Weiner & Hellman LLP
Ms. Sheila Labrecque
Dr. Raymond Lance
Lazarus Marketing Inc.
Mr. Charles Lefkowitz
Marilyn Troy Trust
McDonald's USA
Donald P. McNeice Golf Outing
Mr. and Mrs. Richard D. Nanula
Neil Piper's Community Walk
New Canaan Group, LLC.
Nortel Networks
Mr. and Mrs. Len Novick
Ms. Patricia O'Connor
Oxygen Media Inc.
Mr. and Mrs. William J. Quinn
Mr. & Mrs. Thomas A. Reynolds
Mr. David Salmanson
Ms. Teresa A. Sarno
Mr. Alan D. Schwartz
Seventeenth Street Parking Corp.
Showtime Networks, Inc.
Sierra Consulting Group, Inc.
Ms. Holly Smith Dougherty
Telik, Inc.
The Jim and Linda Robinson
Foundation, Inc.
The John A. Hartford Foundation, Inc.
The John L. & Sue Ann Weinberg
Foundation
The Renee Malca Cadour Corn
Charitable Trust
The Stanley Works, Inc.
Therion Biologics Corporation
Tribune Media Services
Mr. Robert S. Trump
Turner Broadcasting
United Way of Tri-State
Mr. and Mrs. Fred von Stange
Walgreens Company
Wallack Management Company, Inc.
William and Karen Tell Foundation
Mr. and Mrs. Alexander Zecca
$2,500 - $4,999
Anthony Zoine Memorial Fund
Mr. and Mrs. Jerome Belson
Mrs. Amy Berko Iles
Blistex Inc.
Mr. and Mrs. Anthony Bosco
Bovis/Hunt
Mr. and Mrs. Joel Brooks
Mr. David Brown
Ms. Enes J. Carnesecca and
Mr. Gerard Frunzi
Mr. Thomas M. Cheek
Mr. James Cofer
Coinmach
Ms. Patricia Coleman
Court TV
Ms. Ellen Fox
Mr. Bernard Friedman
Fujirebio Diagnostics
Mr. Kevin Gallagher
Mr. Brian Goldman
Gym Source
Mr. and Mrs. Daniel Hartman
Mr. Robert Heller
IBM
Jackson Lewis LLP
Johnson & Johnson
Mr. Kenneth Kerr
Mr. Christopher Kete and
Ms. Tiffany George-Kete
Mr. Charles Klatskin
Ms. Barbara Kushnick
LaValdese Mutual Aid Society
Mr. and Mrs. Robert Lemle
Matassa Construction
Micro Motion, Inc.
Mr. Donald Moriarty
Neil M. Klatskin Foundation, Inc.
New York Yankees Foundation
Mr. and Mrs. Scott C. Paston
Paul Bearducci Memorial Golf Outing
Pfizer Foundation
Quality Building Contractor Inc
Redpath Integrated Pathology, Inc.
Saddle River Valley Club Casino Night
Samsung Electronics of America
Mr. and Mrs. Gregory F. Sarno
Mr. and Mrs. Richard Schmeelk
Setauket Meadows, LLC
Mr. Claude Sherman
Target Corporation
The Andrew M. Weiss Memorial
Foundation
The Chubb Corporation
Dr. Kevin Tomera
$1,000 - $2,499
A & E Television Networks
Accu-Line Productes, Inc
Mr. Stephen M. Ackerman
Mr. and Mrs. Andrew Alberti
American Land Services, Inc.
Mr. Tom Amodio
Mrs. Rosayn D. Anderson
Mr. Philip Arnold
Asseo Griliches Endowment Fund
Aurora Contractors, Inc.
Mr. Bruce Axtman
Mr. Gregory Barton
Mr. and Mrs. David Beam
Beauty Products, Inc.
Mr. Stephen D. Bechtel, Jr.
Belvis Live
Mrs. Leslie Berger
Mr. Gene M. Bernstein
Mr. and Mrs. John R. Bickham
Blago Management Corp
Ms. Maria Blaney
Mr. and Mrs. Lee Blaymore
Ms. Judith Blazer
Boston Red Sox Foundation
Mr. David Braver
Noelle Brower & Friends
Mrs. Mary Elizabeth Bunzel
Ms. Janice Calloway
Mrs. Theresa Campbell
Mr. and Mrs. Thomas M. Capobianco
Mr. & Mrs. Michael Carpenter
Cars 4 Causes
Ms. Rose Caruso
Mr. and Mrs. Frank T. Cary
Casimir Capital, LLP
Centennial Elevator
Chia Family Foundation, Inc.
Circle of Hope
Mr. William J. Christ
Mr. William Claflin IV
Mr. John P. Clarke
Mr. & Mrs. J.D. Clarkson
Mr. Monty Cleworth
CMD Tech Software
Mr. Peter Coen
Mr. Andrew Cohen
Mr. Todd Corkum
Ms. Rose-Ellen David
Ms. Nancy DeRuchie
Mr. and Mrs. Charles Diker
Ms. Ann C. DiTroia
Doran Family Charitable Trust
Ms. Kathleen A. Dore and
Mr. Keith Jepsen
Mr. Glen Dreyer
Dreyer's Grand Ice Cream
Edelman Foundation
Mr. and Mrs. George P. Edmonds
EMC
Mr. and Mrs. Barrett Emmert
Employees of York International
Dr. Jeffrey Epstein and Dr. Ronit Adler
Ernst & Young LLP
Estate of Bessie Wright
Estate of Murray Nadler
Mr. and Mrs. Robert Fagenson
Mrs. Cyrille Farrell
Drs. Randall and Sheryl Feingold
Festival of Hope
Forchelli, Curto, Schwartz, Mineo,
Carlino & Cohn LLP
Mr. Charles Forma
Mr. Robert F. Forrer
Mr. Edward M. Fox
Frederick & Phyllis Doppelt
Philanthropic Fund
Mr. and Mrs. Abel Friedman
Mr. and Mrs. John Fudemberg
Mr. Mario J. Gabelli
Mr. Victor Gallo
Mr. and Mrs. John M. Gaynor
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Genvec, Inc.
Mr. and Mrs. Henry Giugni
GlaxoSmithKline Foundation
Ms. Gloria Glickfeld
Mr. and Mrs. Gary Goldsmith
Ms. Shirley Goldstein
Mr. and Mrs. Stuart D. Goldstein
Ms. Sheila Lopin Goode
Goodwin Procter LLP
Mr. and Mrs. Michael L. Gordon
Ms. Beth Grant
Mr. and Mrs. David Granville-Smith
Greenberg Traurig LLP
Groisser Family & Friends
Mr. and Mrs. Guenther E. Greiner
Mr. and Mrs. Victor W. Groisser
Mr. Craig Gross
Ms. Lauris Halladay
Mr. and Mrs. Robert A. Hamburger
Ms. Marcia Hammer
Mr. and Mrs. Steve Handler
Ms. Margaret Harrington and Family
Ms. Caryn Hasselbring
Ms. Suzanne Hatfield
Hewitt Associates LLC
Hewlett Packart
Mrs. Sue Hills
Mr. Richard Hochman
Mr. C. Dennis Hoffman
Howard L. Willett Foundation Inc.
HRH Construction
Ms. Laura Hull
Mr. and Mrs. Michael Huseby
IAC/InterActiveCorp
Mr. James Iwasaka
Mr. Jarred Jacobs
Jewel Osco
Jones Apparel Group
Mr. Peter Jones
Mr. and Mrs. Paul Kagan
Kaplan Development Group, LLC
Mr. Raymond Katz
Mr. & Mrs. Steven Keefer
Kelley Drye & Warren
Kimera Salon, Inc.
Ms. Kerry Kirby
Ms. Amy Kistler
Mr. Carl Kleidman
Mr. Stanley A. Kochanek
The Koslow Family
Mr. and Mrs. Richard M. Kovacevich
KPMG Peat Marwick Foundation
Black Twig, LLC
Mr. and Mrs. Eugene W. Landy
Ms. Denise Lang
Mr. and Mrs. Michael Laub
Mr. and Mrs. Michael Lefkowitz
Lefkowitz, Louis & Sullivan
Mr. and Mrs. Michael Levin
Mr. David Levine
Ms. Vicki Levine
Levy Organization
Libertas Holdings, LLC
Mr. and Mrs. Howard Lichtenstein
Lifetime Television
Mr. Dennis Lind
Lindenbaum Family Foundation
Loeb & Loeb LLP
Mrs. Marie L. LoRusso
Mr. Andrew Malis
Mr. and Mrs. Barry Manson
Marsh USA Inc.
Ms. Electra Martin
Mr. and Mrs. Gary D. Matson
Mautner-Glick Corp
Ms. Kathleen Mayo
MC Construction Management, Inc.
Ms. Karen McQuade
Ms. Marilyn McVane
Mr. Victor Menezes
Metro One Telecommunications
MGM Transport Corp.
Michael J. Reichey Fund
Microsoft Giving Campaign Program
Mr. and Mrs. G. Edward Montero
Dr. and Mrs. Martin Murphy
Mr. Gene Nadler
Mr. Harry Nadler
National Association of Professional
Mortgage Women
National Grid USA Service Company, Inc.
NCTA
Mr. Philip Nelan
Mr. and Mrs. Ted Newman
NGL Insurance Group
Novell
Mr. and Mrs. Louis Novick
Mr. Stuart Oberman
Mr. and Mrs. Kevin E. O'Brien
Ogilvy Healthworld
Ms. Jeanne C. Olivier
Pat Ericson Memorial Walk
Mr. William Pauker
Mr. Richard Pawlowski
PearlGreen Corporation
Mr. and Mrs. Michael Perlow
Philip W. Riskin Charitable
Foundation, Inc.
Phoenix Environmental
Mr. and Mrs. Daniel B. Plaut
Podell Rothman Schwartz Scheckter &
Bantfield LLP
Portland General Electric Co.
Mr. Robert Principe
Pultes Homes
Mr. John Purcell
Mr. Ray Raimondi
Ms. Denise Ray
Mr. and Mrs. Edward Regan
Ms. Catherine Rein
Ms. Susan Richer
Mr. Brian Richmand
Mr. David Ring and Ms. Elizabeth Chen
Mr. George A. Rippey and
Ms. Linda Paulsen
RJ Aaron Triathlon
Robinson Lerer & Montgomery
Mr. David Rockefeller
Mr. and Mrs. Rick Roesch
Mr. Dan Rogosich
Mr. and Mrs. Richard P. Rosenbaum
Mrs. and Mr. Sandra Rosenbaum
Mr. and Mrs. Andrew Rosengard
Mr. and Mrs. Morton J. Rothberg
Mr. Errol M. Rudman
Mr. Morgan Rutman
Mr. Asheesh Saksena
Salone Di Capelli & Friends
Ms. Betty Santangelo and
Mr. Thomas M. Egan
Mr. Andrew Sarno
Mr. Tim Sarno
Mr. Donald Schneider
Mr. and Mrs. Richard Schneider
Ms. Nancy Schuman
Mr. and Mrs. Martin Schwartz
Scripps Networks
Mr. and Mrs. David Sculnick
Mr. Fraser Seitel
Sewickley Academy
Ms. Eleanor Sheldon
Ms. Grace D. Shepherd
Mr. Barry Shimelfarb
Siegel, O'Connor, Zangari,
O'Donnell & Beck, P.C.
Siemens Caring Hands Foundation
Ms. Susan Spencer
Sperry Product Innovation, Inc
Mr. and Mrs. Steven A. Staines
Mr. and Mrs. Alan Steinberg
Mrs. Maxine Stein-Kohler
Mr. James W. Stevens
Ms. Geraldine Stover
Sustainable Growth Advisers
Syska Hennessy Group
Tanenbaum Harber Co., Inc.
Tracy Windt Fitzgerald Walk
Dr. and Mrs. John Tasiopoulos
Mr. and Mrs. Henry Taub
Dr. Noel Taylor
Mr. Joseph Tetro
The Carmine Fattore Memorial Fund, Inc.
The Chelsey Foundation Trust
The Estate of William D'Arcy Cayton
The Glickenhaus Foundation
The LeBovitz Fund
The Louis J. Kuriansky Foundation, Inc.
The North Face, Inc.
The Odd Lot Club
The Rosenkranz Foundation
Tikkun Olam Founation
Mr. and Mrs. James Tsunis, Jr.
Mr. Jim Tsunis, Sr.
Tupelo Capital Management, Inc.
Ms. Betty Turner
Tyco Matching Gifts Program
Ms. Alina Umansky
Vanguard Charitable Endowment
Program
Mr. Joseph J. Vitale
Mr. Mario P. Vitale
Mr. and Mrs. Drew Weber
Mr. Roger Weber
Mrs. Alexis Weiss
Ms. Inky Weiss
Mr. Matthew Weiss
Mr. and Mrs. Robert Weiss
Mr. Scott Weiss
Ms. Maureen Wimmer
Winding Wood, Inc.
World Reach, Inc.
World Wrestling Entertainment
Ms. Barbara Wriston
Yes Network
donors
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
MARC LUSTGARTEN PANCREATIC
CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)
Balance Sheets
December 31, 2005 and 2004
Assets
Cash and cash equivalents
Investments (note 4)
Interest and dividends receivable
Contributions receivable (note 3)
Prepaid Expenses
Software, furniture, and equipment, net of accumulated
depreciation of $52,561 in 2005 and $50,470 in 2004
Total assets
Liabilities and Net Assets
Liabilities - accounts payable and accrued expenses
Grants Payable
Total liabilities
Net assets - unrestricted
Total liabilities and net assets
$
$
$
$
2005
2004
1,705,841
7,753,435
31,241
413.289
6,679
2,319,962
5,184,270
30,278
282,442
6,056
10,134
9,920,619
3,751
7,826,759
91,742
250,000
341,742
9,578,877
9,920,619
106,488
736,781
843,269
6,983,490
7,826,759
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
MARC LUSTGARTEN PANCREATIC
CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)
Statements of Activities
Years ended December 31, 2005 and 2004
2005
Revenues:
Contributions
Special events, net of costs of direct benefits to donors
of $168,875 in 2005 and $122,450 in 2004
Contributed services (note 2)
Dividends and interest
Total revenues
$
Expenses:
Program services:
Research
Public education and information
Professional education
Total program services
Supporting services:
Management and general
Fund-raising
Total supporting services
Total expenses
Excess (deficiency) of revenues over expenses
Net appreciation in fair value of investments
Increase (decrease) in net assets
Net assets:
Unrestricted, beginning of year
Unrestricted, end of year
$
2004
1,779,872
1,273,162
2,046,476
246,633
275,863
4,348,844
1,655,187
257,691
188,267
3,374,307
442,471
587,444
252,601
1,282,516
2,482,583
369,809
345,446
3,197,838
329,057
173,546
502,603
1,785,119
2,563,725
31,662
2,595,387
421,067
176,839
597,906
3,795,744
(421,437)
154,672
(266,765)
6,983,490
9,578,877
7,250,255
6,983,490
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
special thanks
The board and staff of The Lustgarten Foundation for Pancreatic Cancer Research
would like to extend its deepest appreciation to the many people whose enduring
support and assistance helps to make our work possible.
Special thanks to our Corporate Advisory Board for helping us reach millions of
individuals nationwide through their media and communications outlets, to our Scientific
Advisory Board for providing the leadership necessary to forge real progress in the fight
against pancreatic cancer, and to the many friends who have sponsored our research
funding efforts through generous individual, corporate and foundation gifts.
We wish to acknowledge the dedicated team of professionals at Cablevision Systems
Corporation who provide vital support to the Foundation, including the Departments of
Media and Community Relations, Marketing and Advertising, Accounting, Corporate
Information Systems, Legal Services, Employee Services and Risk Management. Special
thanks to all of the Cablevision affiliates that commit to airing our PSAs each year.
Our sincere gratitude goes to Levon Graphics Corporation for printing services,
Lazarus Marketing for mail house services, Black Twig Communications for design
services and Robinson Lerer & Montgomery for providing strategic public relations
counsel, direction and implementation.
We remain indebted to our volunteers, whose personal commitments of time are
immeasurable. We also wish to acknowledge those individuals and families who have so
thoughtfully chosen to direct charitable gifts to The Lustgarten Foundation in honor of
loved ones. We are privileged to continue our efforts in their names.
Thank you all for lending us your talent and support as we embark upon another year
of challenges and rewards. Most of all, thank you for your heartfelt dedication to our
efforts to understand, prevent, and ultimately cure pancreatic cancer.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
notes
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

1111 Stewart Avenue, Bethpage, NY 11714 P 516-803

Transcription

Similar documents

Borland-Groover Clinic

Mrs. Starr`s Second Grade Class loves going to the computer lab

Funeral Services For Mrs. Jennie Thompson are rteld

Protocol Of Pancreatic Cancer

Welcome to Year 9 2015

2010 Part 2

Anatomía del sistema digestivo

CNTEAEDITION2Newsletter - Colts Neck Township Education

January News: School News: Welcome back

ComQuest Reports - ComQuest Academy Charter High School